SAR 408701

Drug Profile

SAR 408701

Alternative Names: SAR408701

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImmunoGen
  • Developer Sanofi
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 17 Oct 2017 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease, In adults, In the elderly) in Japan (IV) (NCT03324113)
  • 17 Oct 2017 Phase-I clinical trials in Solid tumours (In the elderly, In adults, Late-stage disease, Metastatic disease, Monotherapy) in Japan (IV) (NCT03324113)
  • 30 May 2017 ImmunoGen and Sanofi amends a licensing agreement granting exclusive, fully-paid license of SAR 408701 to Sanofi
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top